2026-10-13T14:45:29.000Z · 4 hours ago Alaunos Therapeutics announces completion of Velaris acquisition
Oct 13, 2026, 10:31 AM EDT · 5 hours ago Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
Oct 13, 2026, 7:00 AM EDT · 8 hours ago Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
2026-09-18T13:20:09.000Z · 25 days ago Alaunos Therapeutics prices 380,469 shares at $1.46 in registered direct offer
Sep 18, 2026, 9:00 AM EDT · 25 days ago Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
2026-05-26T16:02:50.000Z · 4 months ago Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies
May 26, 2026, 11:01 AM EDT · 4 months ago Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
2026-05-18T12:26:37.000Z · 4 months ago Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies
May 18, 2026, 8:00 AM EDT · 4 months ago Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
2026-03-02T11:43:28.000Z · 7 months ago Alaunos Therapeutics reports ‘positive’ proof-of-concept data for ALN1003
Mar 2, 2026, 6:30 AM EST · 7 months ago Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
2025-10-22T10:40:47.000Z · 11 months ago Alaunos Therapeutics files to sell 327,740 shares of common for holders
2025-06-23T17:00:26.000Z · 1 year ago Alaunos prices 610,399 shares at $3.36 in registered direct offering
Jun 23, 2025, 8:00 AM EDT · 1 year ago Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
2025-05-14T12:19:01.000Z · 1 year ago PMGC Capital announces filing to report 5.09% stake in Alaunos Therapeutics ELAB
May 14, 2025, 8:00 AM EDT · 1 year ago PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) ELAB
Nov 14, 2023, 7:30 AM EST · 2 years ago Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
2023-08-16T12:35:15.000Z · 3 years ago Alaunos Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Aug 14, 2023, 4:05 PM EDT · 3 years ago Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
Jun 29, 2023, 7:00 AM EDT · 3 years ago Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
May 25, 2023, 5:00 PM EDT · 3 years ago Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting
May 10, 2023, 7:00 AM EDT · 3 years ago Alaunos Therapeutics Reports First Quarter 2023 Financial Results
May 3, 2023, 8:30 AM EDT · 3 years ago Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
Apr 26, 2023, 12:30 PM EDT · 3 years ago Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Mar 30, 2023, 7:00 AM EDT · 3 years ago Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
Mar 29, 2023, 5:30 PM EDT · 3 years ago Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
Mar 7, 2023, 7:00 AM EST · 3 years ago Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 28, 2023, 4:01 PM EST · 3 years ago Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
Jan 9, 2023, 8:30 AM EST · 3 years ago Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023
Nov 29, 2022, 9:01 AM EST · 3 years ago Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock
Nov 28, 2022, 4:01 PM EST · 3 years ago Alaunos Therapeutics Announces Proposed Public Offering of Common Stock
Nov 14, 2022, 7:00 AM EST · 3 years ago Alaunos Therapeutics Reports Third Quarter 2022 Financial Results
Nov 8, 2022, 8:30 AM EST · 3 years ago Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
Nov 7, 2022, 8:00 AM EST · 3 years ago Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting
Sep 21, 2022, 8:30 AM EDT · 4 years ago Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
Sep 7, 2022, 8:30 AM EDT · 4 years ago Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September
Aug 24, 2022, 3:00 PM EDT · 4 years ago Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
Aug 15, 2022, 7:00 AM EDT · 4 years ago Alaunos Therapeutics Reports Second Quarter 2022 Financial Results
Aug 8, 2022, 8:50 AM EDT · 4 years ago Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022
Aug 4, 2022, 5:00 PM EDT · 4 years ago Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations
Jun 1, 2022, 8:30 AM EDT · 4 years ago Alaunos Therapeutics to Present at the Jefferies Healthcare Conference
May 26, 2022, 5:01 PM EDT · 4 years ago Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting
May 16, 2022, 7:30 AM EDT · 4 years ago Alaunos Therapeutics Reports First Quarter 2022 Financial Results
May 10, 2022, 8:30 AM EDT · 4 years ago Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 9, 2022, 8:30 AM EDT · 4 years ago Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
May 2, 2022, 4:31 PM EDT · 4 years ago Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting
May 2, 2022, 8:30 AM EDT · 4 years ago Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors
Mar 30, 2022, 7:30 AM EDT · 4 years ago Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Mar 16, 2022, 8:30 AM EDT · 4 years ago Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022
Mar 8, 2022, 4:05 PM EST · 4 years ago Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference
Jan 26, 2022, 7:00 AM EST · 4 years ago Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics
Nov 9, 2021, 8:05 AM EST · 4 years ago Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting
Nov 8, 2021, 4:10 PM EST · 4 years ago Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 1, 2021, 4:30 PM EDT · 4 years ago Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021
Sep 27, 2021, 4:05 PM EDT · 5 years ago Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway
Sep 1, 2021, 4:05 PM EDT · 5 years ago Ziopharm Oncology to Participate in September Investor Conferences
Aug 30, 2021, 8:30 AM EDT · 5 years ago Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions